<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5Bnlmid%5D&amp;utm_medium = rsss＆ff = 20250331 230705＆fc = none＆v = 2.18.0.post9+e462414＆utm_source = chrome＆utm_content = 101560960＆utm_campaign =期刊<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_medium=rss&amp;ff=20250331230705&amp;fc=None&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=101560960&amp;utm_campaign=journals" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期二，2025年4月1日03:07:06 +0000</lastbuilddate><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>疫苗诱导的供体特异性HLA抗体：一份报告报告强调了肾移植候补患者的敏感性风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160827/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>结论：RZV或PCV13疫苗或其辅助成分可能会导致肾移植候补患者的敏敏化。 DSA的检测可能会导致对兼容移植的访问降低。随着HLA免疫遗传学的进步，更好的工具可以监测HLA特异性的内存B细胞，以提供对HLA DSA抗体形成的主要作用机理的重要见解，并建议采取干预措施来减轻该内存B细胞激活。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1567377。 doi：10.3389/fimmu.2025.1567377。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：在肾脏移植候补患者中，疫苗接种仍然是预防感染的护理标准。疫苗及其辅助敏化剂可以是诱导供体特异性抗体（DSA）对人白细胞抗原（HLA）的潜在来源。这些新型的HLA抗体可能导致阳性流动池交叉匹配（FCXM），这可能会使先前兼容的活体供体不兼容。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">病例报告：我们提出了一个成年肾移植等候补患者，该患者患有多个负T细胞和B细胞FCXM，在基线时未检测到DSA。然后，患者接受了单剂量的肺炎球菌结合物（PCV13）和第二剂量的重组带状疱疹疫苗（RZV）。这些疫苗接种后，患者的FCXM对T细胞和B细胞均为阳性，HLA I类抗体（A1、23、24、80; B44、45、76）均显示出计算的面板反应抗体（CPRA）51％。检测到A1和B44 DSA预测与患者计划的活供体肾移植不兼容。该患者不得不进入肾脏生产的捐赠计划，并在16个月后接受移植。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：RZV或PCV13疫苗或其辅助成分可能会导致肾移植候补患者的敏敏化。 DSA的检测可能会导致对兼容移植的访问降低。随着HLA免疫遗传学的进步，更好的工具可以监测HLA特异性的内存B细胞，以提供对HLA DSA抗体形成的主要作用机理的重要见解，并建议采取干预措施来减轻该内存B细胞激活。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160827/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160827</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949935/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949935</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1567377>10.3389/fimmu.2025.1567377</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160827</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator>普拉马斯·卡科德卡（Pramath Kakodkar）</dc:creator><dc:creator> Nooshin Shekari</dc:creator><dc:creator>拉胡尔·梅拉（Rahul Mainra）</dc:creator><dc:creator> Destinie Webster</dc:creator><dc:creator> Twyla Pearce</dc:creator><dc:creator>方吴</dc:creator><dc:creator>艾哈迈德·莫斯塔法</dc:creator><dc:date>2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>疫苗诱导的供体特异性HLA抗体：一份报告报告强调了肾移植候补患者的敏感性风险</dc:title><dc:identifier>PMID：40160827</dc:identifier><dc:identifier> PMC：PMC11949935</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1567377</dc:identifier></item><item><title>结合白介素6和EBV DNA水平可预测接受化学免疫疗法的复发或转移性鼻咽癌患者的生存结果</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160826/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>结论：该模型预测了接受化学免疫疗法的R/M NPC患者的PFS和OS。这一发现可能有助于临床医生进行最初的预后估计，但需要对IL-6和EBV DNA的价值进行进一步的前瞻性研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1560897。 doi：10.3389/fimmu.2025.1560897。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：基于铂的化学疗法加PD-1抑制剂（化学免疫疗法）是对复发或转移性鼻咽癌（R/M NPC）的标准系统治疗。但是，预测生存结果的生物标志物仍然不满意。这项研究旨在建立一个简单但易于适用的模型，以预测接受化学免疫疗法的R/M NPC的生存结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">材料和方法：通过化学免疫疗法治疗或在我们医院进行局部治疗的总共319例R/M NPC患者被随机分为训练（n = 223）和验证（n = 96），比为7：3。使用训练集中的常见独立生存期（PFS）和总生存期（OS）创建了一个易于适用的预后风险分组模型。在验证集中评估了模型性能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：预处理IL-6和EBV DNA水平被鉴定为独立的预后因素（在0-4分评分），并用于开发具有独特存活率的预后风险分组模型：0-1点（低风险），2-3点（中间风险）和4点（高风险）。在训练集中，在低，中间和高风险组中分别未达到中位PF（NR），18.90和7.73个月（P &lt;0.001），而中位OS为NR，NR，NR和13.6个月（P &lt;0.001）。在验证集中进一步证实了结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：该模型预测了接受化学免疫疗法的R/M NPC患者的PFS和OS。这一发现可能有助于临床医生进行最初的预后估计，但需要对IL-6和EBV DNA的价值进行进一步的前瞻性研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160826/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160826</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949991/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949991</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1560897>10.3389/fimmu.2025.1560897</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160826</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator>刘</dc:creator><dc:creator>Zilu Huang</dc:creator><dc:creator>陈陈</dc:creator><dc:creator>Yujun Hu</dc:creator><dc:creator> Yalan Tao</dc:creator><dc:creator> Songran Liu</dc:creator><dc:creator> Ping Feng</dc:creator><dc:creator> Shuohan Zheng</dc:creator><dc:creator> Yunfei Xia</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>结合白介素6和EBV DNA水平可预测接受化学免疫疗法的复发或转移性鼻咽癌患者的生存结果</dc:title><dc:identifier>PMID：40160826</dc:identifier><dc:identifier> PMC：PMC11949991</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1560897</dc:identifier></item><item><title>寡头&lt;sup>; tm &lt;/sup>;：应用于癌症免疫疗法的T细胞响应增强平台</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160825/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>背景：肿瘤中得出的（0）是有吸引力的癌症免疫疗法靶标，尤其是与免疫检查点抑制剂（CPI）相结合时。由于T细胞依赖性反应，使用脂质纳米颗粒（LNP）封装的mRNA递送新皮特的疫苗在患者和动物模型中表现出令人鼓舞的结果。但是，低突变负担通常是CPI反应不良的预测指标：针对少数可用突变的免疫反应可能不足。一个... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1549112。 doi：10.3389/fimmu.2025.1549112。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：肿瘤中得出的（0）是有吸引力的癌症免疫疗法靶标，尤其是与免疫检查点抑制剂（CPI）相结合时。由于T细胞依赖性反应，使用脂质纳米颗粒（LNP）封装的mRNA递送新皮特的疫苗在患者和动物模型中表现出令人鼓舞的结果。但是，低突变负担通常是CPI反应不良的预测指标：针对少数可用突变的免疫反应可能不足。对这几种突变的反应增强可能会提高CPI功效。在这里，我们研究了一种自组装序列寡聚™的潜力，以改善鼠类癌模型中的新皮子免疫原性和抗肿瘤功效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：测试了编码与寡聚™融合的短表位字符串的LNP形成的mRNA构建体。比较了寡聚™的构建体及其对照组之间的免疫反应。针对四个肿瘤模型（MC38，CT26，TC-1，B16-OVA）的特异性T细胞反应使用ELISPOT在幼稚的小鼠中测量。进一步选择了两种模型（TC-1和B16-OVA）进行肿瘤生长疗效测试。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与对照组相比，LNP形成的Neopitope-Oligodom™mRNA构建体诱导的免疫反应明显优于测试的对照组。这种提高的特异性免疫原性与鼠类合成癌模型（例如B16-OVA和TC-1）的抗肿瘤生长作用有关。诱导的T细胞免疫反应与肿瘤生长率降低显着相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：组合寡聚™和LNP-MRNA Technologies提供了一个多功能平台，可有效地交付短短的NeoEpitope字符串。这种方法代表了个性化癌症免疫疗法的可行，潜在的有效策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160825/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160825</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11951937/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11951937</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1549112>10.3389/fimmu.2025.1549112</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160825</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator>朱迪思·德尔·坎波（Judith del Campo）</dc:creator><dc:creator> SéverineValsesia</dc:creator><dc:creator>艾尔莎·尼克利（Elsa Nikly）</dc:creator><dc:creator>罗伯托·鲁伊（Roberto Ruiu）</dc:creator><dc:creator> Antonella Iacoviello</dc:creator><dc:creator> Elena Quaglino</dc:creator><dc:creator>费德里卡·卡瓦洛（Federica Cavallo）</dc:creator><dc:creator>达利尔·汉纳尼（Dalil Hannani）</dc:creator><dc:creator> Emilie Boucher</dc:creator><dc:creator>佛罗伦萨·尼古拉斯</dc:creator><dc:creator>亚历山大·勒·佛特（Alexandre Le Vert）</dc:creator><dc:creator> Francesco Doro</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>寡头&lt;sup>; tm &lt;/sup>;：应用于癌症免疫疗法的T细胞响应增强平台</dc:title><dc:identifier>PMID：40160825</dc:identifier><dc:identifier> PMC：PMC11951937</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1549112</dc:identifier></item><item><title> SP-D和IL-10的循环水平增加与Covid-19患者的疾病严重程度和肺纤维化的发展有关</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160824/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>结论：SP-D和IL-10在COVID-19患者的ARDS和肺纤维化发展具有某些预测能力。入院时确定这些细胞因子对于评估199例患者的预后至关重要。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1553283。 doi：10.3389/fimmu.2025.1553283。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：患有严重COVID-19的患者可以快速发展急性呼吸窘迫综合征（ARDS），这进一步增加了患肺纤维化的风险。巨噬细胞极化和不同的细胞因子产生在与COVID-19诱导的ARD或肺纤维化相关的病理生理学中的确切作用尚不清楚。有必要确定可以预测肺纤维化或其他不良后果进展的潜在生物标志物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们分析了从健康个体和CoVID-19患者获得的血浆样本，这些患者根据疾病的严重程度和纤维化的胸部计算机断层扫描（CT）扫描进行分层。通过ELISA确定表面活性剂蛋白D（SP-D），基质金属蛋白酶8（MMP8），Krebs Von Den Lungen-6（KL-6），血管紧张素转换酶2（ACE2）和巨噬细胞极化相关的生物标记物。使用回归模型和接收器操作特征（ROC）曲线收集数据并评估数据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：ARDS患者的SP-D，MMP8的血浆水平高于非警戒患者的血浆水平。与没有纤维化变化的患者相比，患有肺纤维化的患者具有更高的血浆SP-D水平。在指示巨噬细胞极化的生物标志物中，与非ARDS患者相比，在ARDS患者中观察到IL-10的显着增加，可诱导的一氧化氮合酶（INOS）和精氨酸酶-1（ARG-1），而肿瘤坏死因子因子因子-α（TNF-α）被降低。 CT纤维化变化的患者的IL-10的血浆水平也升高，并且与ACE2和ARG-1呈正相关。 ROC曲线结果发现，与其他炎症标志物相比，SP-D在预测肺纤维化和ARD方面显示出更高的功效。 IL-10和传统炎症指标（例如CRP和PCT）具有相似的预测价值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：SP-D和IL-10在COVID-19患者的ARDS和肺纤维化发展具有某些预测能力。入院时确定这些细胞因子对于评估199例患者的预后至关重要。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160824/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160824</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949947/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949947</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1553283>10.3389/fimmu.2025.1553283</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160824</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> XIN PAN</dc:creator><dc:creator>宗申黄</dc:creator><dc:creator>宁宁陶</dc:creator><dc:creator>Chuanjun黄</dc:creator><dc:creator>Shanshan Wang</dc:creator><dc:creator> Zuowang Cheng</dc:creator><dc:creator>鲁尤粉丝</dc:creator><dc:creator>Shuai Liu</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>SP-D和IL-10的循环水平增加与Covid-19患者的疾病严重程度和肺纤维化的发展有关</dc:title><dc:identifier>PMID：40160824</dc:identifier><dc:identifier> PMC：PMC11949947</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1553283</dc:identifier></item><item><title>基于病理信息和实验室血液学指标的非吸烟肺腺癌的预后预测模型的开发：多中心研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160823/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>结论：基于肿瘤TNM阶段，肿瘤大小，白细胞计数，中性粒细胞百分比，淋巴细胞百分比和血红蛋白水平的预后模型有效地预测了非吸烟患者的肺腺癌患者的预后。与目前研究的血液标记相比，我们模型的指标不需要转换，我们的模型为临床实践中的个性化诊断和治疗提供了有用的参考。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1566195。 doi：10.3389/fimmu.2025.1566195。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：开发一个简单而实用的模型来预测非吸烟患者肺腺癌患者的预后存活，通过将一般病理信息与实验室血液学指标相结合。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用COX UNIVARIATE和多变量分析来识别可变指标。基于选定的变量构建了COX比例危害模型，以比较非吸烟患者的肺腺癌的高风险和低风险组之间的生存结果并验证模型的性能。随后，建立了一个诺格图模型，以系统地评估所选变量对预后的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：回顾性地收集了四家医院的非吸烟患者的肺腺癌患者的数据。我们招募了1,172名患者，其中包括372个外部验证数据。多变量分析确定了六个重要变量（ <i>P</i> &lt;0.05）：肿瘤TNM阶段，肿瘤大小，白细胞计数，中性粒细胞百分比，淋巴细胞百分比和血红蛋白水平。我们将这六个变量结合在一起以构建模型。训练集的C索引为0.811（0.780-0.842），此值为0.786（0.737-0.835），在验证集中进行测试集，测试集（0.772-0.847）。这三个数据集的3年总生存期（OUC）下曲线下的面积分别为0.850、0.819和0.860。这些5年的值为0.811、0.771和0.849。基于肿瘤分期的分层分析表明，该模型有效区分了结果（ <i>P</i> &lt;0.0001）。与低风险组相比，高风险组的预后明显较差（ <i>p</i> &lt;0.001）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：基于肿瘤TNM阶段，肿瘤大小，白细胞计数，中性粒细胞百分比，淋巴细胞百分比和血红蛋白水平的预后模型有效地预测了非吸烟患者的肺腺癌患者的预后。与目前研究的血液标记相比，我们模型的指标不需要转换，我们的模型为临床实践中的个性化诊断和治疗提供了有用的参考。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160823/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160823</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949898/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949898</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1566195>10.3389/fimmu.2025.1566195</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160823</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator>运行Xiang</dc:creator><dc:creator> Peihong Hu</dc:creator><dc:creator> Xiaoxiong xiao</dc:creator><dc:creator>温李</dc:creator><dc:creator>小狮子</dc:creator><dc:creator>Jun Li</dc:creator><dc:creator> Wen Zhu</dc:creator><dc:creator>小刘</dc:creator><dc:creator>Qiang li</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>基于病理信息和实验室血液学指标的非吸烟肺腺癌的预后预测模型的开发：多中心研究</dc:title><dc:identifier>PMID：40160823</dc:identifier><dc:identifier> PMC：PMC11949898</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1566195</dc:identifier></item><item><title>肿瘤相关的中性粒细胞研究的全球趋势：书目和视觉分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160822/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>结论：这项研究是第一个采用文献计量方法来可视化棕褐色研究中的趋势和边界的一项。这些发现为该领域的发展提供了宝贵的见解，突出了未来研究和潜在协作机会的关键领域。这项全面的分析是研究人员和从业人员的关键资源，旨在推进棕褐色研究及其在癌症治疗中的应用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1478092。 doi：10.3389/fimmu.2025.1478092。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：与肿瘤相关的中性粒细胞（TAN）在肿瘤进展，免疫反应调节和治疗结果中起着至关重要的作用。尽管在棕褐色研究中取得了重大进步，但缺乏客观地列出该领域的当前状态和趋势的全面书目分析。这项研究旨在通过使用文献计量和知识映射技术在视觉上分析TAN研究的全球趋势来填补这一空白。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们检索了与《科学核心收集》数据库中的棕褐色有关的文章和评论，该数据库涵盖了2012年至2024年的时期。使用文献计量学工具（例如Excel 365，Citespace，Vosviewer和Bibliometrix（R-Studio的R-Tool））分析了数据，以识别关键趋势，有影响力的国家和机构，协作网络。和引文模式。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：书目分析中总共包括61个出版物，显示了过去二十年来TANS研究的显着上升趋势。美国和中国成为了出版物和引文数量最多的主要贡献者。该领域出版物最多的期刊是免疫学领域的前沿，诸如Fridlender ZG之类的著名作者被确定为主要贡献者，他的作品经常被引用。分析强调了主要的研究主题。包括棕褐色在肿瘤微环境调节中的作用，它们在肿瘤促进和抑制中的双重功能以及对棕褐色靶向疗法的探索，新兴的研究热点包括对棕褐色可塑性及其与其他免疫细胞的相互作用的研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究是第一个采用文献计量方法来可视化棕褐色研究中的趋势和边界的一项。这些发现为该领域的发展提供了宝贵的见解，突出了未来研究和潜在协作机会的关键领域。这项全面的分析是研究人员和从业人员的关键资源，旨在推进棕褐色研究及其在癌症治疗中的应用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160822/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160822</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949894/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949894</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1478092>10.3389/fimmu.2025.1478092</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160822</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Shaodong Li</dc:creator><dc:creator>彭东</dc:creator><dc:creator>Xueliang Wu</dc:creator><dc:creator> Zhenhua Kang</dc:creator><dc:creator> Guoqiang Yan</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>肿瘤相关的中性粒细胞研究的全球趋势：书目和视觉分析</dc:title><dc:identifier>PMID：40160822</dc:identifier><dc:identifier> PMC：PMC11949894</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1478092</dc:identifier></item><item><title>神经脊髓炎的临床和实验室特征选择性谱系障碍障碍有或没有脑脊液寡聚体带：具有36个月随访的队列</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160821/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>结论：对于AQP4-IGG阳性NMOSD患者，CSF OCB的阳性与较高的CSF细胞计数有关，并且具有CTD和OAIA的可能性更高。 OCBS+在NMOSD中并不少见，可能会预测更频繁的复发，但不会更严重的疾病。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1536853。 doi：10.3389/fimmu.2025.1536853。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在探讨脑脊液（CSF）寡克隆带（OCB）在临床诊断和评估Optica Spectrum谱障碍（NMOSD）中的重要性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The demographic and clinical data of 143 aquaporin-4 immunoglobulin G (AQP4-IgG)-positive NMOSD patients were collected and analyzed, including the gender, age, clinical symptoms and signs, status of CSF OCBs, location and length of the affected spinal cord vertebral segments, Expanded Disability Status Scale (EDSS) at the first attack and at 36-month follow-up,复发时间在36个月内，伴随的结缔组织疾病（CTD）和其他自身免疫抗体（OAIA）的状态。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：有15名患者（10.5％）对OCB（OCB+）呈阳性。与OCB负（OCB-）负面的OCB+病例相比，伴随CTD [5/15（33.3％） <i>vs</i> 。 11/128（8.6％）， <i>p</i> = 0.014]和OAIA [9/15（60.0％） <i>vs</i> 。 37/128（28.9％）， <i>p</i> = 0.020]。 OCB+患者的CSF细胞计数较高[15.0（27.0）/mm <sup>3</sup> <i>vs。</i> 5.0（12.0）/mm <sup>3</sup> ， <i>p</i> = 0.008]，较高的IgG指数[0.68（0.23） <i>vs</i> 。 0.52（0.15）， <i>p</i> &lt;0.001]，在36个月内复发[2.0（3.0） <i>vs</i> 。 1.0（2.0）， <i>p</i> = 0.039]。与OCBS患者相比，CSF的OCB+患者在CSF中具有多核细胞优势（ <i>P</i> = 0.032）。 OCB+与OCB-患者在病变位置的分布中没有显着差异。受影响的脊髓椎段的长度； CSF蛋白和白蛋白商的浓度； EDSS在腰椎穿刺和36个月的随访时得分，以及发作发作，复发和累积临床综合征（全部<i>p</i> >; 0.05）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：对于AQP4-IGG阳性NMOSD患者，CSF OCB的阳性与较高的CSF细胞计数有关，并且具有CTD和OAIA的可能性更高。 OCBS+在NMOSD中并不少见，可能会预测更频繁的复发，但不会更严重的疾病。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160821/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160821</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949817/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949817</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1536853>10.3389/fimmu.2025.1536853</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160821</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator>温布杨</dc:creator><dc:creator>小刘</dc:creator><dc:creator>Jie Wei</dc:creator><dc:creator> hai yu</dc:creator><dc:creator> Wanqing Wu</dc:creator><dc:creator> Jingguo Wang</dc:creator><dc:creator>博登</dc:creator><dc:creator>小吴</dc:creator><dc:creator>Xiangjun Chen</dc:creator><dc:creator>徐张</dc:creator><dc:date>2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>神经脊髓炎的临床和实验室特征选择性谱系障碍障碍有或没有脑脊液寡聚体带：具有36个月随访的队列</dc:title><dc:identifier>PMID：40160821</dc:identifier><dc:identifier> PMC：PMC11949817</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1536853</dc:identifier></item><item><title>靶向干通路调节巨噬细胞极化并重新编程肿瘤微环境</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160820/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>结论：我们的研究强调了干性抑制剂靶向癌细胞和免疫微环境的双重潜力。这些发现提供了有希望的策略，可以增强间充质样结肠肿瘤中有利的免疫调节。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1513404。 doi：10.3389/fimmu.2025.1513404。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：肿瘤微环境在癌症进展和治疗性耐药性中起关键作用，肿瘤相关的巨噬细胞显着影响免疫抑制和肿瘤的生长。分类为分子亚型4（CMS4）和三阴性乳腺癌亚群的结直肠癌（CRC）特别是具有间质表型，免疫排除和广泛的巨噬细胞浸润的特征。这项研究旨在研究如何使用特定抑制剂靶向癌细胞干，可以在<i>体内</i>调节CRC和<i>乳腺癌</i>中的巨噬细胞极化，从而有可能将免疫平衡从促肿瘤M2样转移到抗肿瘤M1样巨噬细胞。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We used four stemness inhibitors-salinomycin, SB-431542, JIB-04, and napabucasin-each targeting different pathways (Wnt/β-catenin, TGF-β, histone demethylation, and STAT3, respectively), to evaluate their effects on CMS4 CRC cell lines (HCT116 and SW620) and human peripheral blood-derived macrophages在间接共培养模型中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们的结果表明，CMS4 CRC细胞系诱导不同的巨噬细胞极化模式，HCT116促进了M2样巨噬细胞，而SW620倾向于M1样轮廓。值得注意的是，在结直肠癌细胞中，干性抑制剂的组合降低了干性标记（CD133，CD44），并将巨噬细胞极化转移到M1样表型，尤其是在与HCT116的共培养中。使用合同性免疫能力EO771乳腺癌小鼠模型的<i>体内</i>研究表明，干性抑制剂的组合增加了M1/M2巨噬细胞的比率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究强调了干性抑制剂靶向癌细胞和免疫微环境的双重潜力。这些发现提供了有希望的策略，可以增强间充质样结肠肿瘤中有利的免疫调节。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160820/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160820</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11950675/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11950675</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1513404>10.3389/fimmu.2025.1513404</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160820</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Austeja Butkute</dc:creator><dc:creator> Marius Baltramonaitis</dc:creator><dc:creator> Simona Malmige</dc:creator><dc:creator>阿达斯·达林斯卡斯（Adas Darinskas）</dc:creator><dc:creator> Vita Pasukoniene</dc:creator><dc:creator> Agata Mlynska</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>靶向干通路调节巨噬细胞极化并重新编程肿瘤微环境</dc:title><dc:identifier>PMID：40160820</dc:identifier><dc:identifier> PMC：PMC11950675</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1513404</dc:identifier></item><item><title>综合miRNA-mRNA分析发现了贝尔木单抗作用的机制</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160819/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>全身性红斑狼疮（SLE）是一种由自动反应性B细胞驱动的复杂自身免疫性疾病，其特征是致病性自身抗体的产生。 Belimimab是一种抗BAFF单克隆抗体，尽管反应仍然可变，但在降低SLE患者的疾病活性和皮质类固醇中的使用方面已显示出疗效。 B细胞激活因子（BAFF）对于B细胞存活和自身抗体的产生至关重要，将其定位为SLE发病机理的关键靶标。 micrornas ... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1553971。 doi：10.3389/fimmu.2025.1553971。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">全身性红斑狼疮（SLE）是一种由自动反应性B细胞驱动的复杂自身免疫性疾病，其特征是致病性自身抗体的产生。 Belimimab是一种抗BAFF单克隆抗体，尽管反应仍然可变，但在降低SLE患者的疾病活性和皮质类固醇中的使用方面已显示出疗效。 B细胞激活因子（BAFF）对于B细胞存活和自身抗体的产生至关重要，将其定位为SLE发病机理的关键靶标。 MicroRNA（miRNA）是基因表达和免疫稳态的关键调节剂，在SLE病理生理学中具有新兴的作用。但是，它们对抗BAFF疗法（例如Belimimab）的调节仍未得到探索。这项研究研究了在贝拉木单抗治疗前后，研究了来自SLE患者的T细胞，B细胞和髓样细胞中的miRNA-MRNA相互作用。总共确定了与治疗反应和525个miRNA-GENE相互作用相关的79个miRNA。在18个SLE反应者中的验证显示，T和髓样细胞中miRNA表达的显着变化，但在B细胞中却没有。发现Belimimab通过调节BLNK，BANK1和MEF2C等基因以及CD40/CD40L轴来调节B细胞的发育。在T细胞中，miRNA通过NF-κB激活影响干扰素信号传导和炎症细胞因子。以KLF13，CCL5和IL4的下调为特征的髓样细胞的变化似乎是T细胞调节的继发性。这些发现提供了对miRNA介导的调节网络的新见解，使贝拉木单抗在SLE中的免疫调节作用。需要进一步的研究来验证这些发现和通过<i>体外</i>实验，以更好地了解miRNA在指导治疗反应中的作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160819/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160819</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949941/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949941</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1553971>10.3389/fimmu.2025.1553971</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160819</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator>玛丽亚·罗约（Maria Royo）</dc:creator><dc:creator> Blanca Joseph-Mullol</dc:creator><dc:creator>塞巴斯蒂安·桑多瓦尔（Sebastian Sandoval）</dc:creator><dc:creator>特雷莎·莫林（TeresaMoliné）</dc:creator><dc:creator>克里斯蒂娜·索雷（CristinaSolé）</dc:creator><dc:creator> JosefinaCortés-Hernández</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>综合miRNA-mRNA分析发现了贝尔木单抗作用的机制</dc:title><dc:identifier>PMID：40160819</dc:identifier><dc:identifier> PMC：PMC11949941</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1553971</dc:identifier></item><item><title>病例报告：与NF155抗体阳性自身免疫性淋巴结病：与低钠血症发作的一种罕见病例</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160818/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>目的：该病例报告旨在强调诊断为CASPR2相关自身免疫性脑炎和NF155抗体阳性自身免疫性淋巴结（AN）的患者的非典型表现和管理，最初表现为肢体弱点和高钠血症。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1519878。 doi：10.3389/fimmu.2025.1519878。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：该病例报告旨在强调诊断为CASPR2相关自身免疫性脑炎和NF155抗体阳性自身免疫性淋巴结（AN）的患者的非典型表现和管理，最初表现为肢体弱点和高钠血症。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过临床评估和诊断测试来鉴定患者，包括血清和脑脊液分析，神经影像学和神经传导研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：患者表现出肢体弱点，低钠血症，认知异常和周围神经受累。诊断测试表明CASPR2和NF155抗体是阳性的。治疗性干预措施包括皮质类固醇，血浆交换和静脉内免疫球蛋白治疗，然后进行B细胞耗竭治疗。治疗导致步行功能和抗体归一化的改善。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">讨论：该病例报告通过记录CASPR2相关的自身免疫性脑炎和NF155抗体阳性AN的罕见同时发生，并具有独特的低钠血症表现，从而有助于文献。这些发现强调了在患有低钠血症和神经系统症状的患者中考虑自身免疫性病因的重要性。此外，对B细胞耗竭疗法的有利反应提出了针对类似情况的潜在治疗选择。主要的占用是需要在具有复杂神经系统表现的患者中提高临床怀疑和全面的诊断评估，以促进及时的诊断和适当的治疗。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40160818/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160818</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949779/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949779</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1519878>10.3389/fimmu.2025.1519878</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40160818</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Wen-Ya Wang</dc:creator><dc:creator> Jing-ying黄</dc:creator><dc:creator>ying Xue</dc:creator><dc:creator> An-Ran Zhang</dc:creator><dc:creator> Ruo-Yi Guo</dc:creator><dc:creator> Zhen Jia</dc:creator><dc:creator> ya-fei太阳</dc:creator><dc:creator>本·李</dc:creator><dc:date>2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>病例报告：与NF155抗体阳性自身免疫性淋巴结病：与低钠血症发作的一种罕见病例</dc:title><dc:identifier>PMID：40160818</dc:identifier><dc:identifier> PMC：PMC11949779</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1519878</dc:identifier></item><item><title>免疫调节在HBV感染和肝细胞癌中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/40160817/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250331230705＆v = 2.18.0.post9+e462414<description>丙型肝炎病毒（HBV）感染是发育肝细胞癌（HCC）的有据可查的独立危险因素。因此，广泛的研究集中在阐明HBV诱导肝癌发生的机制上。大多数研究致力于了解HBV DNA在宿主基因组中的整合，病毒RNA表达以及所得的蛋白质转录物影响细胞过程并促进肝细胞的恶性转化。然而，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月14日； 16：1506526。 doi：10.3389/fimmu.2025.1506526。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">丙型肝炎病毒（HBV）感染是发育肝细胞癌（HCC）的有据可查的独立危险因素。因此，广泛的研究集中在阐明HBV诱导肝癌发生的机制上。 The majority of studies are dedicated to understanding how HBV DNA integration into the host genome, viral RNA expression, and the resulting protein transcripts affect cellular processes and promote the malignant transformation of hepatocytes. However, considering that most acute HBV infections are curable, immune suppression potentially contributes to the critical challenges in the treatment of chronic infections. Regulatory T cells (Tregs) are crucial in immune tolerance. Understanding the interplay of Tregs within the liver microenvironment following HBV infection could offer novel therapeutic approaches for treating HBV infections and preventing HBV-related HCC. Two viewpoints to targeting Tregs in the liver microenvironment include means of reducing their inhibitory function and decreasing Treg frequency. As these strategies may disrupt the immune balance and lead to autoimmune responses, careful and comprehensive profiling of the patient&#39;s immunological status and genetic factors is required to successfully employ this promising therapeutic approach.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40160817/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160817</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949809/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949809</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1506526>10.3389/fimmu.2025.1506526</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40160817</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Hailong Zheng</dc:creator><dc:creator> Bingchen Xu</dc:creator><dc:creator> Yiyu Fan</dc:creator><dc:creator> Aekkachai Tuekprakhon</dc:creator><dc:creator> Zania Stamataki</dc:creator><dc:creator> Fei Wang</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>The role of immune regulation in HBV infection and hepatocellular carcinogenesis</dc:title><dc:identifier> pmid:40160817</dc:identifier><dc:identifier> pmc:PMC11949809</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1506526</dc:identifier></item><item><title> Insect-specific virus platforms for arbovirus vaccine development</title><link/> https://pubmed.ncbi.nlm.nih.gov/40160816/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250331230705&amp;v=2.18.0.post9+e462414<description> Certain insect-specific viruses (ISVs), specifically the mosquito alphaviruses, Eilat and Yada Yada viruses, and orthoflaviviruses, Binjari, Aripo, YN15-283-02 and Chaoyang viruses, have emerged as potential platforms for generation of whole virus vaccines for human and veterinary applications. These ISVs are remarkably tolerant of the substitution of their structural polyproteins with those of alphaviruses and orthoflaviviruses that are pathogenic in humans and/or animals. The resulting... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 14;16:1521104. doi: 10.3389/fimmu.2025.1521104.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Certain insect-specific viruses (ISVs), specifically the mosquito alphaviruses, Eilat and Yada Yada viruses, and orthoflaviviruses, Binjari, Aripo, YN15-283-02 and Chaoyang viruses, have emerged as potential platforms for generation of whole virus vaccines for human and veterinary applications. These ISVs are remarkably tolerant of the substitution of their structural polyproteins with those of alphaviruses and orthoflaviviruses that are pathogenic in humans and/or animals. The resulting ISV-based chimeric vaccines have been evaluated in mouse models and have demonstrated safety and efficacy in non-human primates, crocodiles and pigs. Targets include chikungunya, Venezuelan and eastern equine encephalitis, dengue, Zika, yellow fever, Japanese encephalitis and West Nile viruses. ISV-based chimeric vaccines provide authentically folded tertiary and quaternary whole virion particle structures to the immune system, a key feature for induction of protective antibody responses. These vaccines are manufactured in C6/36 or C7-10 mosquito cell lines, where they grow to high titers, but they do not replicate in vertebrate vaccine recipients. This review discusses the progress of these emerging technologies and addresses challenges related to adjuvanting, safety, and manufacturing.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40160816/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160816</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949993/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949993</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1521104>10.3389/fimmu.2025.1521104</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40160816</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Roy A Hall</dc:creator><dc:creator> Wilson Nguyen</dc:creator><dc:creator> Alexander A Khromykh</dc:creator><dc:creator> Andreas Suhrbier</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>Insect-specific virus platforms for arbovirus vaccine development</dc:title><dc:identifier> pmid:40160816</dc:identifier><dc:identifier> pmc:PMC11949993</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1521104</dc:identifier></item><item><title> A pooled CRISPR screen identifies the Tα2 enhancer element as a driver of &lt;em>;TRA&lt;/em>; expression in a subset of mature human T lymphocytes</title><link/> https://pubmed.ncbi.nlm.nih.gov/40160815/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250331230705&amp;v=2.18.0.post9+e462414<description> The T cell receptor (TCR) is crucial for immune responses and represents a pivotal therapeutic target for CAR T cell therapies. However, which enhancer elements drive the constitutive expression of the TCRα chain in mature, peripheral T cells has not been well defined. Earlier work has suggested that enhancer alpha is inactive in mature peripheral T cells and that an alternative enhancer element in the 5&#39; J region was driving TRA expression, while more recent findings indicated the opposite.... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 14;16:1536003. doi: 10.3389/fimmu.2025.1536003.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> The T cell receptor (TCR) is crucial for immune responses and represents a pivotal therapeutic target for CAR T cell therapies. However, which enhancer elements drive the constitutive expression of the TCRα chain in mature, peripheral T cells has not been well defined. Earlier work has suggested that enhancer alpha is inactive in mature peripheral T cells and that an alternative enhancer element in the 5&#39; J region was driving <i>TRA</i> expression, while more recent findings indicated the opposite. Here, we applied a pooled CRISPR screen to probe a large genomic region proximal to the human <i>TRA</i> gene for the presence of regulatory elements. Interestingly, no sgRNA targeting the 5&#39; J region was identified that influenced <i>TRA</i> expression. In contrast, several sgRNAs targeting enhancer alpha element Tα2, were identified that compromised the expression of the TCRα chain in Jurkat E6.1, as well as in a subset of human primary T cells. Our results provide new insights into the regulation of <i>TRA</i> in human peripheral T cells, advancing our understanding of how constitutive <i>TRA</i> expression is driven and regulated.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40160815/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160815</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949936/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949936</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1536003>10.3389/fimmu.2025.1536003</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40160815</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Pascal Y Schönberg</dc:creator><dc:creator> Ángela Muñoz-Ovalle</dc:creator><dc:creator> Maciej Paszkowski-Rogacz</dc:creator><dc:creator> Eugenia Crespo</dc:creator><dc:creator> Duran Sürün</dc:creator><dc:creator> Anja Feldmann</dc:creator><dc:creator> Frank Buchholz</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>A pooled CRISPR screen identifies the Tα2 enhancer element as a driver of &lt;em>;TRA&lt;/em>; expression in a subset of mature human T lymphocytes</dc:title><dc:identifier> pmid:40160815</dc:identifier><dc:identifier> pmc:PMC11949936</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1536003</dc:identifier></item><item><title> The impact of the mRNA COVID-19 vaccine on the Th-like cytokine profile in individuals with no history of COVID-19: insights into autoimmunity targeting heat shock proteins</title><link/> https://pubmed.ncbi.nlm.nih.gov/40160814/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250331230705&amp;v=2.18.0.post9+e462414<description> Although some reports suggest that COVID-19 vaccination may exacerbate existing autoimmune diseases or trigger new-onset cases, a definitive causal relationship between the vaccines and these conditions has not been established. Several potential mechanisms have been proposed to explain this association, including: (i) molecular mimicry, which refers to a structural similarity between SARS-CoV-2 and human antigens; (ii) bystander activation, involving both B and T lymphocytes; and (iii) the... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 14;16:1549739. doi: 10.3389/fimmu.2025.1549739.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Although some reports suggest that COVID-19 vaccination may exacerbate existing autoimmune diseases or trigger new-onset cases, a definitive causal relationship between the vaccines and these conditions has not been established. Several potential mechanisms have been proposed to explain this association, including: (i) molecular mimicry, which refers to a structural similarity between SARS-CoV-2 and human antigens; (ii) bystander activation, involving both B and T lymphocytes; and (iii) the effects of adjuvants. In this study, we investigated whether two doses of the mRNA COVID-19 vaccine influenced blood cytokine levels associated with major T helper cell populations, which are known to play a significant role in autoimmunity and revisited the role of the humoral autoimmune response directed against heat shock proteins (Hsps) in individuals with no history of COVID-19. While no significant differences were found in the levels of IFN-γ, IL-6, IL-22, IL-4, IL-8, IL-10, and IL-17A, between vaccinated and unvaccinated people, several positive correlations were observed between serum cytokine levels and circulating autoantibodies directed against self-Hsps exclusively in vaccinated individuals. These findings suggest that the mRNA COVID-19 vaccine does not impact cytokines involved in the pathogenesis of autoimmune diseases. Further research is required to evaluate the safety of COVID-19 vaccination in patients with autoimmune conditions, particularly those in whom anti-Hsps autoantibodies are suspected to contribute to disease development.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40160814/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160814</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11949786/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11949786</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1549739>10.3389/fimmu.2025.1549739</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40160814</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Stefan Tukaj</dc:creator><dc:creator> Magdalena Sitna</dc:creator><dc:creator> Krzysztof Sitko</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>The impact of the mRNA COVID-19 vaccine on the Th-like cytokine profile in individuals with no history of COVID-19: insights into autoimmunity targeting heat shock proteins</dc:title><dc:identifier> pmid:40160814</dc:identifier><dc:identifier> pmc:PMC11949786</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1549739</dc:identifier></item><item><title> Inflammatory profiling and immune cell infiltration in dysthyroid optic neuropathy: insights from bulk RNA sequencing</title><link/> https://pubmed.ncbi.nlm.nih.gov/40160813/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250331230705&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: This is the first study to identify the key molecular and immune drivers of DON through bulk transcriptomic analysis, emphasizing the central role of inflammation-related molecules and immune cell infiltration in its pathogenesis. The identified IRDGs and their associated pathways provide novel insights for innovative diagnostic and therapeutic strategies. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 12;16:1550694. doi: 10.3389/fimmu.2025.1550694.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Dysthyroid optic neuropathy (DON), the most severe complication of thyroid eye disease (TED), has unclear mechanisms and unsatisfactory treatment outcomes. This study aimed to identify key pathways and inflammation-related core genes driving DON progression, potentially informing new therapeutic strategies and improving disease management. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Retro-orbital tissues from DON, non-DON TED, and healthy controls (HCs) were analyzed using bulk RNA sequencing. Differentially expressed genes (DEGs) were identified and subjected to Gene Ontology (GO) enrichment analysis. Weighted gene co-expression network analysis (WGCNA) identified disease-relevant modules. Immune cell infiltration was assessed via single-sample Gene Set Enrichment Analysis (ssGSEA). ROC analysis and single-gene GSEA were used to evaluate the diagnostic potential and functional relevance of core genes. Inflammatory-Related Differential Genes (IRDGS) were identified and preliminarily validated using Quantitative Real-Time PCR. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Differential gene expression analysis revealed 176 and 202 significantly upregulated genes in DON <i>vs.</i> non-DON and DON <i>vs.</i> HCs comparisons, respectively. Notably, inflammation-related genes, including <i>CXCL14, CCL21, HP</i> , and fibrosis-associated genes such as <i>MGP, FN1</i> , and <i>COL11A1</i> , were significantly upregulated in DON group. GO enrichment analyses identified immune-related processes like lymphocyte proliferation, cytokine activity, and extracellular matrix remodeling. WGCNA further identified key gene modules associated with inflammation and tissue remodeling in DON, and IRDCGs, such as <i>CCL21, HP</i> , and <i>SLCO2A1</i> , emerged as the most significant markers. Single-gene GSEA confirmed that these genes are involved in immune response, inflammation, and fibrosis-related processes. Immune cell infiltration analysis using ssGSEA revealed that DON patients exhibited significantly increased infiltration of activated B cells, CD4 T cells, mast cells, and Th1 cells, and correlation analysis showed that IRDGs were significantly associated with multiple immune cell types, particularly activated B cells and regulatory T cells. Finally, qPCR validation of the top 10 IRDEGs in retro-orbital tissues showed that <i>HP, TPSAB1</i> , and <i>PLA2G2A</i> were significantly upregulated in the DON. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This is the first study to identify the key molecular and immune drivers of DON through bulk transcriptomic analysis, emphasizing the central role of inflammation-related molecules and immune cell infiltration in its pathogenesis. The identified IRDGs and their associated pathways provide novel insights for innovative diagnostic and therapeutic strategies.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40160813/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">40160813</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11951427/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250331230705&v=2.18.0.post9+e462414">PMC11951427</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1550694>10.3389/fimmu.2025.1550694</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40160813</guid><pubDate> Mon, 31 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Qintao Ma</dc:creator><dc:creator> Yuanping Hai</dc:creator><dc:creator> Yongbo Duan</dc:creator><dc:creator> Genfeng Yu</dc:creator><dc:creator> Cheng Song</dc:creator><dc:creator> ShengAi Huang</dc:creator><dc:creator> Anqi Huang</dc:creator><dc:creator> Yan Zhu</dc:creator><dc:creator> Yongzhi Shen</dc:creator><dc:creator> Zimeng Huang</dc:creator><dc:creator> Xiao Wang</dc:creator><dc:creator> Lan Liu</dc:creator><dc:creator> Thomas Efferth</dc:creator><dc:creator> Huiyu Guo</dc:creator><dc:creator> Yi Wang</dc:creator><dc:creator> Jie Shen</dc:creator><dc:date> 2025-03-31</dc:date><dc:source>免疫学领域</dc:source><dc:title>Inflammatory profiling and immune cell infiltration in dysthyroid optic neuropathy: insights from bulk RNA sequencing</dc:title><dc:identifier> pmid:40160813</dc:identifier><dc:identifier> pmc:PMC11951427</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1550694</dc:identifier></item></channel></rss>